TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39379838

Group type: EXPERIMENTAL
Intervention: Non-pseudomonal PPM co-isolation
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Pseudomonas co-isolation
Number of subjects: 453
Study: 39379845

Group type: EXPERIMENTAL
Intervention: iCBT Shyness Program (internet-delivered cognitive-behavioral therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommended by a health professional without guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommended by a health professional, with low-intensity guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39379877

Group type: EXPERIMENTAL
Intervention: Suicide Attempts Multi-component Intervention Treatment (SAMIT) - 8 sessions of individual psychotherapy combining Dialectical Behaviour Therapy (DBT), Mentalization-Based Therapy (MBT), and Narrative approaches.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual intervention (TAU)
Number of subjects: 0
Study: 39379885

Group type: EXPERIMENTAL
Intervention: Lipid-containing eye drop (BTC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Commercially available non-lipid eye drops (NLED)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Treatment difference between BTC and NLED
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ocular symptoms
Number of subjects: 158
Study: 39379931

Group type: EXPERIMENTAL
Intervention: Lazertinib 240 mg/day
Number of subjects: 78
Study: 39379942

Group type: EXPERIMENTAL
Intervention: MethyDT test (IColohunter)
Number of subjects: 1194
Study: 39379970

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (2-month follow-up educational and/or cognitive-behavioural interventions)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 130
Study: 39380004

Group type: EXPERIMENTAL
Intervention: Deep learning software for real-time motion tracking
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Deep learning detection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Statistical modelling of study data
Number of subjects: 50
Study: 39380015

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PI) irrigation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard irrigation (control)
Number of subjects: 96
Study: 39380053

Group type: EXPERIMENTAL
Intervention: Breastfeeding - a good start together intervention
Number of subjects: 284
Study: 39380078

Group type: EXPERIMENTAL
Intervention: Automated NEWS2 calculation using wearable devices (wristband with PPG sensor)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional NEWS2 calculation using vital parameters measured by medical staff
Number of subjects: 210
Study: 39380086

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) with 400 mg albendazole
Number of subjects: 0
Study: 39380152

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39380195

Group type: EXPERIMENTAL
Intervention: Low volume high-intensity interval training (LV-HIIT, <10 min at high intensity)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High volume high-intensity interval training (HV-HIIT, >10 min at high intensity)
Number of subjects: 80
Study: 39380259

Group type: EXPERIMENTAL
Intervention: Satralizumab (subcutaneous administration)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Satralizumab exposure and body mass index
Number of subjects: 154
Study: 39380627

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TLM) using smartwatches for continuous monitoring of vital parameters
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (CTL) group
Number of subjects: 108
Study: 39380737

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted excision (VAE) with complete removal of the biopsy target and subsequent cleaning samples.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Typical sampling biopsy (control group).
Number of subjects: 140
Study: 39380911

Group type: EXPERIMENTAL
Intervention: THC-dominant edible cannabis
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CBD-dominant edible cannabis
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Combined THC and CBD edible cannabis
Number of subjects: 249
Study: 39380954

Group type: EXPERIMENTAL
Intervention: Patient-specific dosimetry for DTC patients receiving radioiodine (RAI) therapy
Number of subjects: 30
Study: 39380967

Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg once daily) and capecitabine (1000 mg/m2)
Number of subjects: 78
Study: 39381003

Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE vaccination
Number of subjects: 0
Study: 39381032

Group type: EXPERIMENTAL
Intervention: TBR for assessing fluoride uptake in PET-active lesions
Number of subjects: 7
Study: 39381416

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT) with technology support
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT) without technology support
Number of subjects: 168

Group type: COMPARATOR
Intervention: Moderate-Intensity Training (MIT)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HIT (with and without technology support)
Number of subjects: 168
Study: 39381542

Group type: EXPERIMENTAL
Intervention: COHEC programme (cardiac coherence and medical hypnosis sessions, starting 7 days before the procedure)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: COHEC programme (cardiac coherence and medical hypnosis sessions)
Number of subjects: 53
Study: 39381591

Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Support (remote coaching and technical assistance, supplemented with in-person visits)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Support
Number of subjects: 14

Group type: COMPARATOR
Intervention: Routine Implementation Support
Number of subjects: 14
Study: 39381594

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 200
Study: 39381608

Group type: EXPERIMENTAL
Intervention: BRIDGE intervention plus service-as-usual
Number of subjects: 40

Group type: COMPARATOR
Intervention: Service-as-usual alone
Number of subjects: 40
Study: 39381651

Group type: EXPERIMENTAL
Intervention: Elagolix (300 mg) twice daily with add-back therapy (estradiol [1 mg] and norethindrone acetate [0.5 mg] once daily)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study: 39381777

Group type: EXPERIMENTAL
Intervention: Multimodal sensor-based eHealth intervention during 14 video sessions of cognitive-behavioral therapy (CBT)
Number of subjects: 20
Study: 39381816

Group type: EXPERIMENTAL
Intervention: Usual care + integrated digital psychological intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 420
Study: 39381850

Group type: EXPERIMENTAL
Intervention: velmanase alfa 1 mg/kg once weekly
Number of subjects: 21
Study: 39381863

Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa 2 mg/kg every 4 weeks for 52 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa
Number of subjects: 30
Study: 39382077

Group type: EXPERIMENTAL
Intervention: Patient navigator programmes
Number of subjects: 2895

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2895
Study: 39382091

Group type: EXPERIMENTAL
Intervention: Intensive screening for early detection of BK viraemia or BK viruria
Number of subjects: 2669

Group type: COMPARATOR
Intervention: Fluoroquinolones
Number of subjects: 2669
Study: 39382222

Group type: EXPERIMENTAL
Intervention: Once-daily screening and pressure-supported SBT
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Once-daily screening and T-piece SBT
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: More frequent screening and pressure-supported SBT
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: More frequent screening and T-piece SBT
Number of subjects: 797

Group type: COMPARATOR
Intervention: More frequent screening vs once-daily screening with pressure-supported SBT
Number of subjects: 797

Group type: COMPARATOR
Intervention: Once-daily screening and pressure-supported SBT vs T-piece SBT
Number of subjects: 797
Study: 39382234

Group type: EXPERIMENTAL
Intervention: Extracorporeal blood purification (EBP) device connected to the CPB circuit
Number of subjects: 343

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 343
Study: 39382244

Group type: EXPERIMENTAL
Intervention: Remote daily multidisciplinary rounds led by a board-certified intensivist through telemedicine, monthly audit and feedback meetings, provision of evidence-based clinical protocols.
Number of subjects: 17024

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 17024

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (daily multidisciplinary rounds).
Number of subjects: 17024
Study: 39382241

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusion triggered by hemoglobin <9 g/dL; n=408)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion triggered by hemoglobin <7 g/dL; n=442)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 850

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 850
Study: 39382446

Group type: EXPERIMENTAL
Intervention: First-line anti-angiogenesis therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line anti-angiogenesis therapy
Number of subjects: 0
Study: 39382587

Group type: EXPERIMENTAL
Intervention: Red LED
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrared LED
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LED associated
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (G-C)
Number of subjects: 0
Study: 39382718

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: pembrolizumab-chemotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: EXTREME
Number of subjects: 67
Study: 39382852

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF) from the first day of 33 gestational weeks to delivery (expected 8 weeks)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF) from the first day of 33 gestational weeks to 4 weeks postpartum (expected 12 weeks)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (expected 8 weeks)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (expected 12 weeks)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Both groups (TAF intervention)
Number of subjects: 239
Study: 39382856

Group type: EXPERIMENTAL
Intervention: Self-expanding valve (SEV)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Balloon-expandable valve (BEV)
Number of subjects: 621
Study: 39382898

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 60

Group type: COMPARATOR
Intervention: In-person consultation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scheduling navigation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Historical cohort without scheduling navigation
Number of subjects: 60
Study: 39382937

Group type: EXPERIMENTAL
Intervention: Parent empowerment intervention based on nursing education (PEINE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 39383026

Group type: EXPERIMENTAL
Intervention: Preoperative acupuncture; details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified
Number of subjects: 0
Study: 39383382

Group type: EXPERIMENTAL
Intervention: Convalescent plasma and standard treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 35
Study: 39383445

Group type: EXPERIMENTAL
Intervention: Sanguineous cardiopulmonary bypass prime
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Immunomodulatory interventions targeting complement
Number of subjects: 40
Study: 39383458

Group type: EXPERIMENTAL
Intervention: Gene therapy with elivaldogene autotemcel (eli-cel)
Number of subjects: 67
Study: 39383459

Group type: EXPERIMENTAL
Intervention: Elivaldogene autotemcel (eli-cel) gene therapy
Number of subjects: 32
Study: 39383612

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Second-line immunosuppressants (SLI)
Number of subjects: 21
Study: 39383771

Group type: EXPERIMENTAL
Intervention: naporafenib plus rineterkib (naporafenib 400 mg BID, rineterkib 200 mg QD)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: naporafenib plus trametinib (naporafenib 200 mg BID, trametinib 1 mg QD)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: naporafenib plus trametinib (naporafenib 400 mg BID, trametinib 0.5 mg QD)
Number of subjects: 216
Study: 39384067

Group type: EXPERIMENTAL
Intervention: Cendakimab 360 mg once weekly for 48 weeks
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Cendakimab 360 mg once weekly for 24 weeks followed by cendakimab 360 mg every other week for 24 weeks (with matching placebo on alternative weeks)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo once weekly for 48 weeks
Number of subjects: 399
Study: 39384087

Group type: EXPERIMENTAL
Intervention: Benzoate 1000 mg/day
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Benzoate 500 mg/day
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Benzoate 750 mg/day
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 39384142

Group type: EXPERIMENTAL
Intervention: Stable isotope-based breath test of intestinal sucrase activity
Number of subjects: 0
Study: 39384194

Group type: EXPERIMENTAL
Intervention: BMS-986156 (30 mg) with ipilimumab (3 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BMS-986156 (100 mg) with ipilimumab (3 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BMS-986156 with ipilimumab and SABR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BMS-986156 (30 mg) with nivolumab (480 mg) and SABR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BMS-986156 with ipilimumab or nivolumab
Number of subjects: 50
Study: 39384203

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 119
Study: 39384222

Group type: EXPERIMENTAL
Intervention: 100% autologous platelet-rich plasma (APRP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 100% autologous serum (AS)
Number of subjects: 96
Study: 39384223

Group type: EXPERIMENTAL
Intervention: Test 1 spectacle lenses
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control lenses
Number of subjects: 256
Study: 39384224

Group type: EXPERIMENTAL
Intervention: Sit-and-stand desk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 39384235

Group type: EXPERIMENTAL
Intervention: Group-based, structured, 1-year, advanced dietary education based on a Mediterranean diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (gluten-free diet without adequate dietary control)
Number of subjects: 0
Study: 39384237

Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 66
Study: 39384241

Group type: EXPERIMENTAL
Intervention: CAS+IMD 1200 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CAS+IMD 2400 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CAS+IMD (1200 mg or 2400 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CAS+IMD
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 39384243

Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 39384245

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham Group (non-stimulation)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: DBS and VNS
Number of subjects: 64
Study: 39384342

Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73m²
Number of subjects: 10205

Group type: EXPERIMENTAL
Intervention: eGFR < 90 mL/min/1.73m²
Number of subjects: 10205

Group type: EXPERIMENTAL
Intervention: Adjustment for frailty
Number of subjects: 10205
Study: 39384451

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg b.i.d.) + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Placebo + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Olaparib + Abiraterone
Number of subjects: 743

Group type: COMPARATOR
Intervention: Placebo + Abiraterone
Number of subjects: 743
Study: 39384609

Group type: EXPERIMENTAL
Intervention: MGTA-145 (0.03 mg/kg) intravenously with plerixafor subcutaneously
Number of subjects: 25

Group type: COMPARATOR
Intervention: Plerixafor
Number of subjects: 25
Study: 39384614

Group type: EXPERIMENTAL
Intervention: Intranasal human milk (IHM) therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Historic HM-fed infants (Control)
Number of subjects: 37
Study: 39384649

Group type: EXPERIMENTAL
Intervention: Kidney transplantation (KTx)
Number of subjects: 19
Study: 39384685

Group type: EXPERIMENTAL
Intervention: SB5 (adalimumab biosimilar)
Number of subjects: 911
Study: 39384691

Group type: EXPERIMENTAL
Intervention: Training PCPs with a half-day course on default choice approach using a decision aid (DA)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group received a 1-h refresher training on smoking cessation aids
Number of subjects: 287
Study: 39384712

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day) with standard medical therapy (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with standard medical therapy (Group B)
Number of subjects: 40
Study: 39384742

Group type: EXPERIMENTAL
Intervention: Envafolimab plus lenvatinib and TACE
Number of subjects: 38
Study: 39384801

Group type: EXPERIMENTAL
Intervention: Sunitinib plus exemestane (25mg for 3 weeks followed by 1 week off or 37.5mg continuous) for 6 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sunitinib plus exemestane
Number of subjects: 18
Study: 39384859

Group type: EXPERIMENTAL
Intervention: Music-Assisted Relaxation (MAR)
Number of subjects: 9
Study: 39385046

Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec (1.33 × 10^14 vg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39385099

Group type: EXPERIMENTAL
Intervention: Local cold application (n=30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local heat application (n=30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local vibration application (n=30)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 39385104

Group type: EXPERIMENTAL
Intervention: Node-sparing modified short-course radiotherapy (25 Gy/5 fractions, 5 Gy/f) followed by CAPOX and tislelizumab
Number of subjects: 32
Study: 39385217

Group type: COMPARATOR
Intervention: OD(-) group (withdrawal of life-sustaining therapies without planned organ donation)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: OD(+) group (withdrawal of life-sustaining therapies with planned organ donation)
Number of subjects: 206
Study: 39385223

Group type: EXPERIMENTAL
Intervention: Moderate-intensity supervised aerobic training for six months
Number of subjects: 50
Study: 39385224

Group type: EXPERIMENTAL
Intervention: Nutrient plus ultra-processed warning labels
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Nutrient warning labels
Number of subjects: 1004
Study: 39385279

Group type: EXPERIMENTAL
Intervention: Concussion-focused cognitive behavioral therapy (cf-CBT)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Parenting skills training (PST)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Care management (CM)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Combination of cf-CBT, PST, and CM
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 368
Study: 39385323

Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction (DBR)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Central-axial single-bundle reconstruction (CASBR)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Anatomical single-bundle reconstruction (ASBR)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: DBR
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: CASBR
Number of subjects: 191

Group type: COMPARATOR
Intervention: ASBR
Number of subjects: 191
Study: 39385327

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus non-steroidal aromatase inhibitor (anastrozole or letrozole)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 311
Study: 39385523

Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62% (40.5 mg/day for 16 weeks)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62%
Number of subjects: 246
Study: 39385595

Group type: EXPERIMENTAL
Intervention: Citrulline Malate (6 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (6 g of corn starch)
Number of subjects: 20
Study: 39385752

Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine (DTaP-IPV-HB-Hib)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pentavalent vaccine (DTwP-HB-Hib)
Number of subjects: 100
Study: 39385774

Group type: EXPERIMENTAL
Intervention: Genetic associations with obesity-related SNPs and PRS
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Food cues exposure during fMRI
Number of subjects: 151
Study: 39385952

Group type: EXPERIMENTAL
Intervention: Distal GM stress
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Proximal GM stress
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GM resilience
Number of subjects: 159
Study: 39386177

Group type: EXPERIMENTAL
Intervention: High-dose Tacrosolv (5 µg tacrolimus/eye/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 39386211

Group type: EXPERIMENTAL
Intervention: Autologous anti-CD20 CAR T cells manufactured using CliniMACS Prodigy®
Number of subjects: 0